PepGen (PEPG) Times Interest Earned (2021 - 2026)
PepGen (PEPG) posted Times Interest Earned of -$611.03 for Q1 2026, up 28.51% sequentially from -$854.71 in Q2 2025, and down 1.45% YoY from -$619.99 in Q1 2025.
PepGen (PEPG) Times Interest Earned (2021 - 2026) Analysis & Trends
PepGen has reported Times Interest Earned for 6 years, with the latest figure at -$611.03 in Q1 2026.
- Quarterly Times Interest Earned fell 1.45% year-over-year to -$611.03 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2620.4 (down 24.71% YoY) and the FY2025 annual result came in at -$6.41, up 80.3% from the prior year.
- Times Interest Earned advanced to -$611.03 in Q1 2026 per PEPG's latest filing, from -$854.71 in the prior quarter.
- Over five years, Times Interest Earned peaked at -$0.58 in Q1 2023 and troughed at -$1544.7 in Q3 2024.
- A 5-year average of -$401.28 and a median of -$42.12 in 2024 frame the typical range for Times Interest Earned.
- The sharpest annual moves came in 2023 and 2024: Times Interest Earned jumped 87.91% in 2023, then tumbled 170084.18% in 2024.
- Over 5 years, Times Interest Earned stood at -$0.8 in 2022, then plunged by 3433.91% to -$28.24 in 2023, then slumped by 49.16% to -$42.12 in 2024, then tumbled by 1929.27% to -$854.71 in 2025, then gained by 28.51% to -$611.03 in 2026.
- According to Business Quant data, Times Interest Earned over the past three periods registered -$611.03, -$854.71, and -$602.33 for Q1 2026, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | PepGen | 207.09 Mn | 207.09 Mn | - | -215.22 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -215.22 |
| Mar 31, 2026 | -611.03 |
| Jun 30, 2025 | -854.71 |
| Mar 31, 2025 | -602.33 |
| Dec 31, 2024 | -42.12 |
| Sep 30, 2024 | -1,544.73 |
| Jun 30, 2024 | -533.77 |
| Mar 31, 2024 | -989.90 |
| Dec 31, 2023 | -28.24 |
| Sep 30, 2023 | -2.97 |
| Jun 30, 2023 | -0.70 |
| Mar 31, 2023 | -0.58 |
| Dec 31, 2022 | -0.80 |
| Mar 31, 2022 | -4.81 |
| Dec 31, 2021 | -1.01 |